10 years: Our International Linked Clinical Trials (iLCT) programme
This successful and pioneering drug-repurposing initiative has advanced treatments for Parkinson's and some iLCT trials are actively seeking participants now.
We fund research that
slows, stops or reverses Parkinson’s
Understanding Parkinson's
In Parkinson’s a protein called alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic. Cure Parkinson's is investigating how this and other key biochemical pathways and events contribute to the progression of Parkinson's. Thanks to our supporters, we’re funding research into the most promising therapeutic areas.
Find out moreThe ADepT-PD trial to target the toxic protein in Parkinson’s
Cure Parkinson's is continually searching for ways to slow, stop or even reverse Parkinson's. That's why we're funding a sub-study within the main ADepT-PD trial to investigate whether nortriptyline can impact disease progression. This sub-study will employ wearable technology along with standard methods of clinical evaluation.
Find out more here
Take part in research
PD Frontline #GetTrialReady
PD Frontline is a remote study offering online genetic testing for people with Parkinson’s, so they can be referred to appropriate clinical trials and other studies. The registration process is designed to be quick and easy to navigate, and it only takes 10 minutes to complete!
Donate
Please consider donating today to help us progress our research with urgency towards a cure
Fundraising events
Advocate spotlight
Omotola Thomas, London
Omotola was diagnosed with early onset Parkinson’s in 2016, aged 35. She is passionate about raising awareness of Parkinson’s and, as the founder/director of Parkinson’s Africa, she works to support, connect and empower African’s affected by the condition.
Read more of her story
